Pasithea Therapeutics Corp
KTTA
Company Profile
Business description
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Contact
1111 Lincoln Road
Suite 500
Miami BeachFL33139
USAT: +1 786 977-3380
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,308.90 | 21.00 | 0.25% |
| CAC 40 | 7,555.87 | 17.89 | -0.24% |
| DAX 40 | 22,425.83 | 154.16 | 0.69% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,463.46 | 46.12 | 0.55% |
| HKSE | 22,035.35 | 27.24 | 0.12% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 35,954.54 | 114.55 | 0.32% |
| NZX 50 Index | 11,903.31 | 122.14 | -1.02% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,095.10 | 24.50 | 0.30% |
| SSE Composite Index | 3,282.47 | 4.18 | -0.13% |